Presentation (CTI)

OBJECTIVES: To assess magnitude of PIP among adults living in the US aged 65 years or older in 2025.
METHODS: This study used a curated US administrative healthcare claims data source that aggregates data from numerous payor and health system sources into a single population. The study period spanned January 1, 2025 to December 31, 2025. Patients were included if they were aged ≥65 years old as of the earliest date of enrollment in 2025, had continuous enrollment for at least one month of the year, and had ≥1 claims for a dispense of a PIP during 2025. Medications deemed potentially inappropriate were defined using 2023 AGS Updated Beers Criteria. Patients’ clinical and demographic characteristics were assessed descriptively, as was PIP type(s) received.
RESULTS: A total of 4,295,818 (17.4% of all in the database) were aged ≥65 years and had ≥1 months of continuous enrollment in 2025; 1,924,024 (44.8%) had ≥1 claims for a PIP in 2025. Mean (SD) age of patients who received PIP was 75.6 (9.8) years, 57.4% were female, and 71.3% were White. Most (83.3%) patients were Medicare enrollees; 12.4%, commercial insurance; and 4.3%, Medicaid. The most common comorbidities were hypertension (62.4% of those who received PIP had this condition) and diabetes (32.0%). The most commonly prescribed PIPs were related to gastrointestinal issues (omeprazole [23.3% received this therapy], pantoprazole [17.6%]), and analgesia (meloxicam [10.6%]).
CONCLUSIONS: More than two in five older patients received PIP in 2025. As medications designated as PIP are associated with poor clinical outcomes and increased healthcare spending, improved methods of identifying those at high risk of potentially inappropriate prescribing are needed. Further research is needed to better understand how Artificial Intelligence methods could be leveraged to readily identify and intervene among those at elevated risk of PIP to optimize patient care and related outcomes.